Form 4: Blueprint Medicines CSO Sells Shares to Cover Tax Obligations

Blueprint Medicines Corporation's Chief Scientific Officer, Percy H. Carter, sold 1,051 shares of common stock at $128.25 per share to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Percy H. Carter, Chief Scientific Officer of Blueprint Medicines Corp (BPMC), sold 1,051 shares of common stock.
• The transaction occurred on July 3, 2025, at a price of $128.25 per share.
• Following this sale, Carter beneficially owns 53,155 shares of common stock.
• The sale was non-discretionary, executed automatically to cover tax withholding obligations associated with the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell to cover' for tax purposes, which is a neutral event and does not reflect discretionary selling by the insider. It's an expected part of equity compensation.

Management Comments

• The sale reported represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Stakeholder Impact

• Shareholders: The sale is a non-discretionary transaction for tax purposes and is generally not viewed as a negative signal regarding management's confidence in the company's future. It slightly increases the public float but is a minor amount relative to total shares outstanding.

Key Dates

Keywords

Blueprint Medicines, BPMC, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Percy H. Carter, Chief Scientific Officer